Project Grant R01CA307360
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $528K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $388,616 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct prospective clinical validation of dynamic BH3 profiling as a functional biomarker for guiding treatment selection in patients with relapsed or refractory acute myeloid leukemia. The project develops and tests a novel assay that measures changes in apoptotic priming in leukemia cells after short ex vivo drug exposure. Dynamic...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Institutes of Health National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $463,279 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate USP1 inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer. The research will confirm the cytotoxic effects of the USP1 inhibitor RO7623066 in ovarian cancer cells and xenograft models harboring homologous recombination alterations, with particular focus on...
- The Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $778,092.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. This research aims to develop innovative immunotherapeutic approaches to achieve cures for this aggressive form of ovarian cancer. DFCI, a...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $721,653 on June 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma. The research program combines molecular mechanistic studies with in vivo mouse models to validate whether O-mannosylation of the KIAA1549 fusion protein is necessary for gliomagenesis and to evaluate POMT complex...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $1.547 million in project grant R37CA295653 on September 17, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Dana-Farber will develop and deploy ACTIVATE, an open-source AI-driven tool to improve cancer clinical trial feasibility assessment and patient-trial matching. The tool extends Dana-Farber's existing MatchMiner platform to extract clinical variables—including cancer type, stage,...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...